Tenderwize
Wróć do wyszukiwania

Rivaroxaban (ATC B01AF01)

AOK - Die Gesundheitskasse in Hessen·Bad Homburg, Germany·Deadline Feb 01, 2027 · 160 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V (Open-House-Modell)

5/100

Ocena szansy

High riskLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

5 / 100

Złożoność

20 / 100

Czynniki ryzyka

The only lot (Rivaroxaban) is cancelled. No new contracts will be concluded under this notice for that active ingredien...

No estimated value, award criteria, or detailed eligibility criteria. This makes it impossible to assess the value or c...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Weak opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Mar 2027
  • Conclude non-exclusive discount agreements for finished medicinal products (Open House model).
  • Only specified active ingredient: Rivaroxaban (ATC B01AF01) – but this lot is cancelled.
Pokaż pełne podsumowanie

This is an Open House model (non-exclusive discount agreements under §130a Abs. 8 SGB V) for finished medicinal products. The only listed lot (Rivaroxaban) is being cancelled as of 30 September 2025, with no new contracts. The overall submission deadline is 1 February 2027, but electronic submission is not allowed (email submission mentioned in XML notice). No estimated value, award criteria, or detailed eligibility criteria are provided. The tender appears to be a correction of a previous notice.

Ryzyka

The only lot (Rivaroxaban) is cancelled. No new contracts will be concluded under this notice for that active ingredien...

No estimated value, award criteria, or detailed eligibility criteria. This makes it impossible to assess the value or c...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Contractors must be able to supply finished medicinal products with specified active ingredients.
  • Agreements are non-exclusive and follow the Open House model.
  • Contracts can be terminated early if AOK Hessen conducts an exclusive tender for the same active ingredients.

Kryteria udzielenia

Lot 1

No award criteria specified for this lot.

Zamawiający

Lokalizacja

Bad Homburg, DEU

Identyfikator

DE114110216

Działalność

Health

Części (1)

LOT-0001

Rivaroxaban (ATC B01AF01)

This lot is cancelled as of 30 September 2025. No contracts will be concluded. A new procedure will be published. Scope: pharmaceutical product Rivaroxaban.

SuppliesEU fundedElectronic submission

Lokalizacja

Germany

Czas trwania

Mar 2025 - Mar 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria specified for this lot.

Szczegóły zamówienia

Data publikacji
20 Aug 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
546345-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3